Researchers have developed a microfluidic chip that can capture rare clusters of circulating tumor cells, which could yield important new insights into how cancer spreads. The work was funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health.
Nanoengineers at the University of California, San Diego developed a gel filled with toxin-absorbing nanosponges that could lead to an effective treatment for skin and wound infections caused by MRSA (methicillin-resistant Staphylococcus aureus), an antibiotic-resistant bacteria. This "nanosponge-hydrogel" minimized the growth of skin lesions on mice infected with MRSA - without the use of antibiotics. The researchers recently published their findings online in Advanced Materials.
Sorrento Therapeutics, Inc., announced today that NantPharma, founded by Dr. Patrick Soon-Shiong and a member of the NantWorks ecosystem of companies, agreed to acquire the rights to Cynviloq through the acquisition of Igdrasol, Inc., a wholly-owned subsidiary of Sorrento, which has been developing Cynviloq (paclitaxel nanoparticle polymeric micelle) in a bio-equivalence trial.
For the second year, the Cincinnati Cancer Center (CCC) has awarded $160,000 in pilot grants to members and basic scientists who are collaborating to find out more about various cancers with hopes of generating more data and additional funding.
Celsion Corporation, a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today reported the publication of an abstract in the prestigious Journal of Controlled Release summarizing findings from a preclinical study confirming effective delivery of RNA to lung cells.
Attacking the perennial problem of systemic toxicity from typical chemotherapy treatments, Dartmouth investigators, led by Barjor Gimi, PhD, have engineered therapeutic cells encapsulated in nanoporous capsules to secrete antitumor molecules from within the tumor.
Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced it is expanding its ongoing Phase 1 study of DCR-MYC in solid tumors, multiple myeloma, or lymphoma to include a cohort of patients with pancreatic neuroendocrine tumors (PNETs) following early signs of clinical and metabolic response and tumor shrinkage in PNET patients.
Celsion Corporation, a fully integrated oncology drug development company, today announced that results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented in poster session at the 2015 American Society of Clinical Oncology (ASCO) meeting in Chicago on Saturday, May 30th. GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein
Dicerna Pharmaceuticals, Inc., a leader in the development of RNAi therapeutics, today announced that new clinical data from a Phase 1 study of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2, 2015 in Chicago.
Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.